Financial Data and Key Metrics Changes - The company reported a revenue of R$625 million in Q4 2024, down 33% year-on-year, primarily due to the reduction of non-core revenue [15][19] - Consolidated net revenue fell by 17.4% year-on-year, with Oi Solutions accounting for 65% of total revenue, which decreased by 24.3% year-on-year [18][19] - Routine operating expenses were R$2 billion, reflecting a 16% reduction year-on-year, while routine costs excluding rental and insurance showed a 37.7% annual reduction [22][23] Business Line Data and Key Metrics Changes - Oi Solutions, the main service component, generated R$409 million in revenue, representing 65% of total revenue, with 34% of its revenues coming from information technology services [15][19] - The company recorded R$1.3 billion from discontinued operations, with the fiber business contributing R$1.1 billion [16] - Cloud-based services revenue increased by 11% year-on-year, while unified and collaborative communications revenues grew by 20% [21] Market Data and Key Metrics Changes - The company has made significant progress in migrating from the concession regime to the authorization regime, which is expected to enhance operational efficiencies [5] - The cash balance at the end of the period was R$1.8 billion, a 35% increase in the quarter [29] Company Strategy and Development Direction - The company is focused on becoming a leaner and more efficient organization, prioritizing high-margin segments and optimizing capital allocation [17][24] - The strategy includes the sale of non-core assets and a commitment to transparency throughout the transformation process [32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges but emphasized the focus on recovering B2B revenues and profitability, as well as optimizing operations post-reorganization [32] - The company aims to minimize the impact of legacy operations on cash flow after the migration to the authorization model [32] Other Important Information - The company completed a capital increase, with credit supporters capitalizing part of their credits, resulting in them holding just under 80% of the company’s stock [4] - The operational cash burn was offset by the net redemption of a deposit in court as part of the debt reduction agreement [30] Q&A Session Summary Question: What are the estimated savings from the sales of Oi fiber, landline telephones, and Oi TV? - Management referred to a specific note in the P&L for details and indicated that the arbitration process timeline is uncertain, hoping for an initial decision within the year [40] Question: What is the plan regarding the remaining copper? - The company is committed to selling all underground copper to V. tal, while air copper will continue with Oi and be negotiated as scrap [42] Question: When can we expect a positive routine EBITDA from ClientCo? - Management stated that ClientCo had a negative EBITDA and could not guarantee a positive outcome in the second quarter due to ongoing legacy operations [54] Question: What is the status of property sales and the expected revenue? - Management indicated that the status of property sales would be presented at the appropriate time, with monitoring by Deloitte to ensure transparency [56] Question: How much copper is left to be sold? - The amount of copper left is variable and depends on market conditions, with extraction costs being a significant factor [47]

Clearside Biomedical (CLSD) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Victor Chong - Chief Medical Officer and EVP, Head of Research & DevelopmentGeorge Lasezkay - President and Chief Executive OfficerCharles Deignan - Chief Financial OfficerJon Wolleben - Managing DirectorDebanjana Chatterjee - DirectorVictor Chong - Chief Medical OfficerYi Chen - Managing Director, Equity ResearchEka G - Director - Equity Research Conference Call Participants Serge Belanger - Senior AnalystDani ...

Lululemon (LULU) Q4 2025 Earnings Call March 27, 2025 04:30 PM ET Company Participants Howard Tubin - Vice President of Investor RelationsCalvin McDonald - CEOMeghan Frank - Chief Financial OfficerAlexandra Straton - Equity Research Managing DirectorBrooke Roach - Vice President - Equity ResearchDana Telsey - CEO and Chief Research OfficerLorraine Hutchinson - Managing DirectorMichael Binetti - Senior Managing DirectorJohn Kernan - Managing DirectorPaul Lejuez - Managing DirectorJay Sole - Managing Director ...

Gevo (GEVO) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Eric Frey - VP of Finance & StrategyPatrick Gruber - CEO & DirectorLynn Smull - Chief Financial OfficerChris Ryan - President, Chief Operating OfficerPaul Bloom - Chief Business OfficerNate Pendleton - Vice PresidentEthan Fingerer - Financial Advisor, Executive Director-InvestmentsJames Arett - Financial Advisor Conference Call Participants Amit Dayal - Managing Director & Senior Technology AnalystPeter Gastreich - Managing Di ...

Braze (BRZE) Q4 2025 Earnings Call March 27, 2025 04:30 PM ET Company Participants Christopher Ferris - Head - IRBill Magnuson - Co-Founder, Chairman & Chief Executive OfficerIsabelle Winkles - Chief Financial OfficerArjun Bhatia - Co-Group Head - Technology, Media & CommunicationsBrian Peterson - Managing DirectorDerrick Wood - Managing DirectorNicholas Altmann - Director - U.S. Software Equity ResearchScott Berg - Managing DirectorYun Kim - Managing Director Conference Call Participants Ryan MacWilliams - ...

INmune Bio (INMB) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants David Moss - Chief Financial OfficerRaymond Tesi - CEO & ChairmanGeorge Farmer - Managing DirectorMark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerCJ Barnum - Head of NeuroscienceDenis Reznik - Senior Equity Research AssociateElemer Piros - Senior Managing Director Conference Call Participants Thomas Shrader - Equity Research AnalystJames Molloy - Managing Director, Senior Biotechnology & Specialty Ph ...

SeaStar Medical Holding (ICU) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Jackie Kosman - Investor Relations AdvisorEric Schlorff - CEOTim Varacek - SVP - Commercial & Business OperationsKevin Chung - Chief Medical OfficerDavid Green - CFO Operator Good afternoon, and thank you for standing by. My name is Calvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Seastar Star Medical Year End twenty twenty four Financial Results Conf ...

P3 Health Partners (PIII) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Ryan Halsted - Managing DirectorAric Coffman - CEOLeif Pedersen - Chief Financial OfficerAmir Bacchus - Co-Founder and Chief Medical OfficerAaron Wukmir - Healthcare Equity Research AssociateJoshua Raskin - Partner - Managed Care & ProvidersDavid Larsen - Managing Director Conference Call Participants Ryan Langston - Director & Senior Analyst - Healthcare ResearchJack Sampson - Analyst Operator Good day and welco ...

Bioatla (BCAB) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Bruce Mackle - Managing DirectorJay Short - Co-Founder, CEO & ChairmanRichard Waldron - Chief Financial OfficerEric Sievers - Chief Medical OfficerSheri Lydick - Chief Commercial OfficerTony Butler - Senior Managing Director Conference Call Participants Jeet Mukherjee - AnalystNone - AnalystArthur He - Analyst Operator is now my pleasure to turn the conference over to Mr. Bruce Mackle of LifeSci Advisors. Please go ahead, s ...

GeoVax Labs (GOVX) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants David Dodd - Chairman, President & CEOMark Reynolds - CFOJohn Sharkey - Vice President of Business DevelopmentKelly McKee - Chief Medical OfficerLaura Suriel - Equity Research Associate Conference Call Participants Max Gadicke - Investor relations & Senior AnalystJonathan Aschoff - Managing Director, Senior Research AnalystRobert Leboyer - Senior Biotechnology Analyst Operator Good afternoon, and welcome everyone to the ...